Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer
Merck KGaA agreed to acquire Silence Therapeutics for $1.1B, gaining its lead drug divesiran, which is in development for polycythemia vera, a rare blood cancer. The deal includes Silence's siRNA platform technology and is expected to close in Q1 2027, pending regulatory and shareholder approval. According to Silence, the acquisition follows a competitive process and aligns with Merck's strategy to expand its rare disease portfolio.
How this was made
The 30-second read
Why it matters
The deal adds a late‑stage asset and siRNA platform to Merck's rare‑disease strategy, potentially enhancing its competitive position against Takeda and PharmaEssentia.
Market read
First‑report M&A of over $1 billion in biotech, likely moving both stocks and influencing sector sentiment.
What to watch
Regulatory approval risk for divesiran and integration challenges could delay value realization.
Background
Merck KGaA, a German pharma group, announced a cash acquisition of UK‑based Silence Therapeutics, bringing in a Phase‑2‑validated siRNA drug for polycythemia vera.
Market effects
Strengthens the biotech siRNA segment and may spur further M&A activity in rare‑disease space.
European biotech valuations could see uplift as a high‑profile German firm expands its pipeline.
Adds to the global trend of large pharma acquiring niche biotech assets to fill pipeline gaps.
Counterpoint
Merck may overpay if Phase 3 fails, leading to a future write‑down and share price pressure.
Key entities
- companyMerck KGaA
German pharmaceutical company acquiring Silence Therapeutics.
- companySilence Therapeutics
UK biotech developing the siRNA drug divesiran for polycythemia vera.
